对未来的克罗恩病治疗有希望的II期生物药物
Pauline Wils1,2, Silvio Danese3, Laurent Peyrin-Biroulet4,5
1Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2, Lille, France.
新的生物药物对克罗恩氏病 (CD) 治疗有希望,为不响应患者提供希望. 需要进一步的研究来确认中度至重度CD患者的长期安全性和疗效.
科学领域:
- 胃肠道学和免疫学
- 药物开发 药物开发
- 临床试验 临床试验
背景情况:
- 克罗恩氏病 (CD) 管理面临着不响应患者和治疗不耐受性的挑战.
- 对于CD的新型治疗策略,存在重大未满足的需求.
研究的目的:
- 在中度至重度CD的II期临床试验中审查生物药物的疗效和安全性数据.
- 讨论CD治疗中新生物疗法的未来前景.
主要方法:
- 对PubMed进行二期试验 (2017-2022) 的文献综述.
- 包括来自ClinicalTrials.gov和大会摘要的正在进行的II期试验.
- 针对IL-23p19,IL-6,粘附分子和抗纤维化机制的生物制剂的分析.
主要成果:
- 一些生物药物,包括IL-23p19抑制剂 (guselkumab,mirikizumab,brazikumab),IL-6抑制剂和抗粘附分子 (ontamalimab),显示出有希望.
- 针对抗纤维细胞机制 (抗TL1A,抗IL-36受体) 的新药正在开发中.
- 一些新兴生物制剂在早期试验中表现出良好的安全性.
结论:
- 新的生物疗法为中度至重度的CD提供了潜在的进展.
- 第三期试验对于验证疗效和长期安全至关重要.
- 对各种作用机制的持续研究对于改善CD患者的治疗结果至关重要.
更多相关视频
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Drugs for Treatment of Ulcerative Colitis in IBD
